跳至主要内容
临床试验/NL-OMON53517
NL-OMON53517招募中不适用

AirWaze - easy and advanced tools for CBCT guided lung interventions - AirWaze

Philips0 个研究点目标入组 37 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Philips
入组人数
37

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age 18 years or older at the time of informed consent.
  • ASA physical status between 1 and 3.
  • Subject is willing and able to give written informed consent for clinical
  • investigation participation prior to the procedure.
  • Subject has a pulmonary lesion with an indication for diagnostic evaluation
  • following current clinical guidelines and/or as decided by multi-disciplinary
  • team consultation.
  • Suitable for CBCT-guided endobronchial nodule biopsy under general
  • anaesthesia.
  • Pre-procedural (PET-)CT scan is available prior to the CBCT-NB intervention.

排除标准

  • Aged 17 or younger at the time of informed consent.
  • ASA physical status is equal to and greater than 4.
  • Not willing or not able to give informed consent.
  • Does not indicate diagnostic evaluation with navigation bronchoscopy.
  • Not suitable for CBCT-guided endobronchial nodule biopsy via navigation
  • bronchoscopy under general anaesthesia.
  • There is no recent pre-procedural (PET-)CT scan available.
  • Known bleeding disorders.
  • Contra-indication for temporary interruption of the use of anticoagulant
  • therapy, such as acenocoumarol, warfarin, therapeutic dose of low molecular
  • weight heparins, clopidogrel, or analogues, NOACs).
  • Known allergy for lidocaine or other allergies interfering with the procedure.
  • Uncontrolled pulmonary hypertension.
  • Recent and/or uncontrolled cardiac disease.
  • Compromised upper airway (e.g. concomitant head and neck cancer or central
  • airway stenosis for any reason such that endobronchial access is considered
  • Potentially confounding drug or device trial during the course of the
  • clinical study. Co-enrollment in concurrent trials may be allowed provided
  • pre-approval is obtained from the Philips Clinical Study Manager.
  • All vulnerable subjects, such as immune-compromised subjects, subjects
  • lacking the capacity to provide consent, patients in emergencies, pregnant or
  • breastfeeding women, or any other subject who meets exclusion criteria,
  • according to applicable national laws, if any.
  • Woman of childbearing potential who is known to be pregnant on admission.
  • Any condition that in the judgment of the investigator could impose hazards
  • to the patient if study therapy is initiated or affect the participation of the
  • subject in the study.
  • Subject is Philips employee or their family members residing with this
  • Philips employee.

研究者

发起方
Philips

相似试验